Page 47 - Acute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) PÉCS, Hungary and BUDAPEST, Hungary, March 04, 2021 (GLOBE NEWSWIRE) -- TurnSole Biologics (TurnSole) today announced the start of a Phase I/II open-label study for Azacytidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20-50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients in Severe Infection with Risk of Progression as Add-on Therapy to Standard of Care, continued with a Randomized, Controlled, Open-Label Adaptive Phase II part to Determine Efficacy and Safety. Coronavirus disease 2019 (COVID-19) is defined as illness caused by a n...

(1) Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada. Ingrid Holmes, Vice Pres...

New York Times: An inflammatory syndrome has erupted in some children in recent weeks.

(MENAFN - Nxtgen Reports) XYZ-research offers a comprehensive analysis of key market trends in the global ACUTE CARE NEEDLELESS CONNECTOR market. It also includes discussion on historical trends, current market status, competitive landscape, growth opportunities and challenges which are backed by factful feedbacks. Global markets continue to sink as the coronavirus spreads, reaching over 200 countries in total by the end of March. Now the outbreak continued to grow, as the number of cases in USA, Italy, Spain, Germany, France all spiked, Europe and USA have now become the epicenter of the o...

XORTX Therapeutics Inc.: XORTX to Present at BIO CEO and Investor Conference; Strategies to Decrease Acute and Chronic Kidney Injury, Co-morbidity and Mortality XORTX Therapeutics Inc. XORTX" or the " Company") (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company is participating in the BIO CEO and Investor Digital Conference to be held virtually February 16-18, 2021. Dr. Allen Davidoff, XORTX's President and CEO will provide an overview of the Company's upcoming, first-in-class kidney di...